Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data

Abstract

The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting $4 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician's choice (methotrexate or bexarotene) in CD30- expressing mycosis fungoides (MF) or primary cutaneous anaplastic large-cell lymphoma (C-ALCL). Cutaneous T-cell lymphomas often cause pruritus and pain; brentuximab vedotin improved skin symptomburdenwith no negative effects on quality of life.We report final data from ALCANZA (median follow-up, 45.9 months). Adults with previously treated CD30- expressingMF/C-ALCLwere randomly assigned to brentuximab vedotin (n564) or physician's choice (n 5 64). Final data demonstrated improved responses per independent review facility with brentuximab vedotin vs physician's choice: ORR4; 54.7% vs 12.5% (P